bibliographic entry 7573943 [be/7573943]
https://w3id.org/oc/corpus/be/7573943

is a
content
  • Kovacs, CS, Seshiah, V, Swallow, R, Jones, R, Rattunde, H, Woerle, HJ, Broedl, UC. EMPA-REG PIO™ Trial Investigators. Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial. Diabetes Obes Metab 2014; 16: 147–158. PMID: 23906415
references